Immunovant
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immunovant and other ETFs, options, and stocks.About IMVT
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor.
CEOEric Venker
CEOEric Venker
Employees362
Employees362
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2018
Founded2018
Employees362
Employees362
IMVT Key Statistics
Market cap5.44B
Market cap5.44B
Price-Earnings ratio-9.41
Price-Earnings ratio-9.41
Dividend yield—
Dividend yield—
Average volume2.32M
Average volume2.32M
High today$27.69
High today$27.69
Low today$26.50
Low today$26.50
Open price$26.58
Open price$26.58
Volume2.67M
Volume2.67M
52 Week high$28.08
52 Week high$28.08
52 Week low$12.72
52 Week low$12.72
Stock Snapshot
The current Immunovant(IMVT) stock price is $26.90, with a market capitalization of 5.44B. The stock trades at a price-to-earnings (P/E) ratio of -9.41.
On 2025-12-17, Immunovant(IMVT) stock moved within a range of $26.50 to $27.69. With shares now at $26.90, the stock is trading +1.5% above its intraday low and -2.9% below the session's peak.
Trading activity shows a volume of 2.67M, compared to an average daily volume of 2.32M.
Over the past 52 weeks, Immunovant(IMVT) stock has traded between a high of $28.08 and a low of $12.72.
Over the past 52 weeks, Immunovant(IMVT) stock has traded between a high of $28.08 and a low of $12.72.
Analyst ratings
79%
of 14 ratingsBuy
78.6%
Hold
21.4%
Sell
0%
People also own
Based on the portfolios of people who own IMVT. This list is generated using Robinhood data, and it’s not a recommendation.